Literature DB >> 27993814

Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.

B Gyawali1, Y Ando2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27993814     DOI： 10.1093/annonc/mdw667

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.

Authors:  Pierre I Karakiewicz; Emanuele Zaffuto; Anil Kapoor; Naveen S Basappa; Georg A Bjarnason; Normand Blais; Rodney H Breau; Christina Canil; Darrel Drachenberg; Sebastien J Hotte; Claudio Jeldres; Michael A S Jewett; Wassim Kassouf; Christian Kollmannsberger; Luke T Lavallée; Ranjena Maloni; Francois Patenaude; Frédéric Pouliot; M Neil Reaume; Robert Sabbagh; Bobby Shayegan; Alan So; Denis Soulières; Simon Tanguay; Lori Wood; Marco Bandini
Journal:  Can Urol Assoc J       Date:  2018-06       Impact factor: 1.862

Review 2.  Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials.

Authors:  Chris Blick; Alastair W S Ritchie; Timothy Eisen; Grant D Stewart
Journal:  Nat Rev Urol       Date:  2017-08-01       Impact factor: 14.432

3.  Low-value practices in oncology contributing to financial toxicity.

Authors:  Bishal Gyawali
Journal:  Ecancermedicalscience       Date:  2017-03-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.